A global opportunity is currently being unlocked via a combination with leading in-market immunotherapies (KEYTRUDA® and YERVOY®) creating a clear path to market in area of high unmet need.
I am pretty sure there was a faster path to market that bypassed stage 3 trials if there is a ‘high unmet need’ using lots of stage 2 data, given enough participants in the stage 2 trials.. maybe China is the answer..
There has been lots of talk on here about big farma accumulating lots of patients that we need to increase our participation numbers..
Maybe China is an untapped resource for cancer patients that need trials.. if we can accumulate enough data a path rapid path to market is a possibility..
VLA Price at posting:
82.0¢ Sentiment: Buy Disclosure: Held
